United-Guardian, Inc. logo

United-Guardian, Inc.

UG

NASDAQConsumer DefensiveHousehold & Personal Products

Latest quote

$7.105

+$0.025 · +0.35%

Aug 21, 3:59 PM ET

UG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

77

Undervalued

Momentum

44

Neutral

Sentiment

60

Mixed

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.

Industry
Household & Personal Products
Sector
Consumer Defensive
Headquarters
US
CEO
Donna Vigilante
Listed since
Mar 17, 1980
Employees
24

Market position

Volume
9.95K
1.41× average
Average volume
7.05K
Average daily volume
Market cap
32.85M USD
Beta
0.96
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
27.05M USD
P/E (TTM)
13.24×
P/B (TTM)
2.82×
P/S (TTM)
2.93×
EV / EBITDA
9.83×
Earnings yield
7.44%
Free cash flow yield
6.74%
Dividend yield
4.20%

Profitability & efficiency

Gross margin
45.93%
Operating margin
20.82%
Net margin
22.00%
Return on equity
18.75%
Return on assets
16.06%
Return on invested capital
15.62%

Financial health

Debt / equity
Current ratio
7.31×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends63%47%32%16%Gross margin, FY2021: 58.74%Gross margin, FY2022: 52.78%Gross margin, FY2023: 49.66%Gross margin, FY2024: 53.03%Gross margin, FY2025: 47.73%Operating margin, FY2021: 40.68%Operating margin, FY2022: 31.79%Operating margin, FY2023: 26.30%Operating margin, FY2024: 29.94%Operating margin, FY2025: 21.27%Net margin, FY2021: 33.44%Net margin, FY2022: 20.23%Net margin, FY2023: 23.71%Net margin, FY2024: 26.69%Net margin, FY2025: 19.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 58.74%. Gross margin FY2022 52.78%. Gross margin FY2023 49.66%. Gross margin FY2024 53.03%. Gross margin FY2025 47.73%. Operating margin FY2021 40.68%. Operating margin FY2022 31.79%. Operating margin FY2023 26.30%. Operating margin FY2024 29.94%. Operating margin FY2025 21.27%. Net margin FY2021 33.44%. Net margin FY2022 20.23%. Net margin FY2023 23.71%. Net margin FY2024 26.69%. Net margin FY2025 19.97%.

Income trends

Revenue

10.55M USD-13.43%

Operating income

2.24M USD-38.48%

Net income

2.11M USD-35.23%
Income trends across reported periods15.11M USD10.38M USD5.65M USD923.35K USDRevenue, FY2021: 13.93M USDRevenue, FY2022: 12.7M USDRevenue, FY2023: 10.89M USDRevenue, FY2024: 12.18M USDRevenue, FY2025: 10.55M USDOperating income, FY2021: 5.67M USDOperating income, FY2022: 4.04M USDOperating income, FY2023: 2.86M USDOperating income, FY2024: 3.65M USDOperating income, FY2025: 2.24M USDNet income, FY2021: 4.66M USDNet income, FY2022: 2.57M USDNet income, FY2023: 2.58M USDNet income, FY2024: 3.25M USDNet income, FY2025: 2.11M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.93M USD. Revenue FY2022 12.7M USD. Revenue FY2023 10.89M USD. Revenue FY2024 12.18M USD. Revenue FY2025 10.55M USD. Operating income FY2021 5.67M USD. Operating income FY2022 4.04M USD. Operating income FY2023 2.86M USD. Operating income FY2024 3.65M USD. Operating income FY2025 2.24M USD. Net income FY2021 4.66M USD. Net income FY2022 2.57M USD. Net income FY2023 2.58M USD. Net income FY2024 3.25M USD. Net income FY2025 2.11M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.55M USD12.18M USD10.89M USD12.7M USD13.93M USD
Cost of goods sold5.51M USD5.72M USD5.48M USD6M USD5.75M USD
Gross profit5.03M USD6.46M USD5.41M USD6.7M USD8.18M USD
Research and development463.64K USD456.78K USD463.99K USD490.77K USD478.64K USD
Operating expenses2.79M USD2.81M USD2.54M USD2.66M USD2.51M USD
Interest income365.31K USD434.68K USD306.65K USD236.7K USD233.86K USD
Interest expense1.62M USD
Depreciation and amortization108.2K USD95.89K USD105.68K USD135.4K USD145.98K USD
Operating income2.24M USD3.65M USD2.86M USD4.04M USD5.67M USD
Net income2.11M USD3.25M USD2.58M USD2.57M USD4.66M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.16

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.230.170.110.05Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 8, 2024: actual 0.19, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 21, 2025: actual 0.11, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 0.12, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual 0.14, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual 0.06, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual 0.14, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 8, 2026: actual 0.18, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 0.16, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.36B2.24B1.12B1.92MQ4 '24MissQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 8, 2024: actual 3.06B USD, estimate 3.12B USD, surprise -1.76%, Miss. Q1 2025, reported Mar 21, 2025: actual 2.48M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 2.48M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual 2.84M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual 2.26M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual 2.96M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 8, 2026: actual 2.87M USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 3.11M USD, estimate —, surprise —, Comparison unavailable.

UG news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.60

2025 complete year-23.1% since 2020

2026 partial: $0.30

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 28, 2026

$0.30

Semi-Annual

Record Jul 28, 2026 · Payment Aug 4, 2026

Dividend

Ex-dividend Jul 25, 2025

$0.25

Semi-Annual

Record Jul 25, 2025 · Payment Aug 1, 2025

Dividend

Ex-dividend Feb 10, 2025

$0.35

Semi-Annual

Record Feb 10, 2025 · Payment Feb 18, 2025

Dividend

Ex-dividend Jul 23, 2024

$0.35

Semi-Annual

Record Jul 23, 2024 · Payment Jul 31, 2024

Dividend

Ex-dividend Feb 9, 2024

$0.25

Semi-Annual

Record Feb 12, 2024 · Payment Feb 20, 2024

Dividend

Ex-dividend Jul 25, 2023

$0.10

Semi-Annual

Record Jul 26, 2023 · Payment Aug 2, 2023

UG peers

Continue in GoAI

Research UG

research.disclaimer